Form 4: Verona Pharma Director James Brady Awarded 96,000 Restricted Share Units

Director James Aloysius Brady receives 96,000 Restricted Share Units (RSUs) in Verona Pharma plc, vesting quarterly starting August 1, 2025.

Summary

• James Aloysius Brady, a director of Verona Pharma plc, was granted 96,000 Restricted Share Units (RSUs) on April 25, 2025.
• Each RSU represents the right to receive one American Depositary Share (ADS), which in turn represents eight ordinary shares of Verona Pharma.
• The RSUs will vest in four equal installments of 25% each, on August 1, 2025, November 1, 2025, February 1, 2026, and May 1, 2026.
• Vesting is contingent upon Mr. Brady's continued service to Verona Pharma on each of those dates.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard compensation practice, aligning director interests with shareholders. No immediate financial impact, but positive for long-term incentives.

Positives

• The granting of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Granting RSUs to directors is a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Equity compensation for directors in the pharmaceutical industry varies widely based on company size, performance, and stage of development.
• Comparing Verona Pharma's RSU grants to those of similar-sized biotech companies would provide a better understanding of whether this grant is above or below industry averages.
• Companies like BioCryst Pharmaceuticals or Catalyst Pharmaceuticals could be used as benchmarks for comparison.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholder value creation.
• Employees: The grant signals confidence in the company's future and may boost morale.

Key Dates

Keywords

Verona Pharma, Restricted Share Units, RSU, Director, James Aloysius Brady, Vesting, ADS, Ordinary Shares, Compensation, Equity